Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer

Abstract

The response to treatment is substantially varied between individual patients with ovarian cancer. However, chemotherapy treatment plans rarely pay sufficient attention to the mentioned factors. Instead, standardized treatment protocols are usually employed for most ovarian cancer patients. Variations in an individual's sensitivity to drugs significantly limit the effectiveness of treatment in some patients and lead to severe toxicities in others. In the present investigation, a nanotechnology‐based approach for personalized treatment of ovarian carcinoma (the most lethal type of gynecological cancer) constructed on the individual genetic profile of the patient's tumor is developed and validated. The expression of predefined genes and proteins is analyzed for each patient sample. Finally, a mixture of the complex nanocarrier‐based targeted delivery system containing drug(s)/siRNA(s)/targeted peptide is selected from the pre‐synthesized bank and tested in vivo on murine cancer model using cancer cells isolated from tumors of each patient. Based on the results of the present study, an innovative approach and protocol for personalized treatment of ovarian cancer are suggested and evaluated. The results of the present study clearly show the advantages and perspectives of the proposed individual treatment approach.

Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog

“…Due to the complex and heterogeneous nature of PDAC's tumor microenvironment, employing multifunctional nanoparticles that combine tumor-penetrating peptides such as TAT, antennapedia, and iRGD could possibly improve the precision and efficiency of targeting, leading to enhanced intracellular delivery of therapeutic agents. Combining the targeting nano-based carriers with gene-silencing approaches, such as RNAi tailored to the specific genetic makeup of patients, holds considerable promise for advancing personalized medicine [6]. This approach could markedly improve therapeutic outcomes and benefit patients with various genetic profiles.…”

“…The size, type and composition of liposomes were selected based on our previous investigations in order to provide the most effective delivery to cancer cells and of the maximal anticancer drug efficacy in vivo [6,9,30,31]. DSPE-PEG 2000 -OCT was synthesized using the methods described below; matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF-MS) confirmed the final yield.…”

“…These factors notably amplify its tendency to metastasize and resist drugs, making it difficult for conventional chemotherapy treatments to deliver therapeutic agents effectively [3][4][5]. Nanotechnology has risen as a critical field in tackling the complexities of diverse cancer types through innovative therapeutic and diagnostic approaches [6][7][8][9]. The versatility and potential of this domain have led to its growing prominence, especially in improving treatments for conditions such as PDAC, making substantial progress in recent years [10].…”

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

“…Recently, we proposed an individual approach for treating ovarian carcinoma, which can be successfully used for treating other cancers, including PDAC [118]. This approach includes the analysis of the expression of genes responsible for the development and progression of the selected cancer type and cancer cell resistance to chemotherapy.…”